The Use of Recombinant Factor VIIa in Platelet Disorders: Thrombocytopenia and Thrombocytopathia

SUMMARY Recombinant FVlla is considered nowadays an universal hemostatic agent while its primary role has been for treatment of hemophilic patients with inhibitors. Its unique mode of action makes FVlla a usefull tool to induce hemostasis in patients with defective thrombin generation with severe bleeding diathesis. The use of rFVlla in thrombocytopathic and thrombocytopenic associated bleeding disorders is discussed.